Halomethanes
Search Within Results
1
–
1
of
1
results
1
![Medchemexpress LLC N-[5-({2-[(cyclopropylcarbonyl)amino]-imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-... | 1005780-62-0 | MFCD23160045 | 99.7% | 445.47 g·mol⁻1 | C23H23N7O3 | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000287464.png-250.jpg)
Medchemexpress LLC N-[5-({2-[(cyclopropylcarbonyl)amino]-imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-... | 1005780-62-0 | MFCD23160045 | 99.7% | 445.47 g·mol⁻1 | C23H23N7O3 | 10 MG
TAK-593 is a small-molecule tyrosine kinase inhibitor originally developed by Takeda Pharmaceutical Company. It potently inhibits vascular endothelial growth factor receptors and platelet-derived growth factor receptors and has demonstrated anti-angiogenic and antitumor activity in preclinical studies. Reported biochemical IC50 values include 3.2 nM (VEGFR1), 0.95 nM (VEGFR2), 1.1 nM (VEGFR3), 4.3 nM (PDGFRα), and 13 nM (PDGFRβ).
- Potent VEGFR and PDGFR inhibition (VEGFR2 IC50 ≈ 0.95 nM).
- High biochemical selectivity toward receptor tyrosine kinases.
- Reported molecular formula C23H23N7O3 and molecular weight ≈ 445.47 g·mol⁻1.
- High purity, typically reported as 99.66% by supplier.
- Provided with analytical documentation such as LC-MS.
- Suitable for preclinical studies of angiogenesis and tumor biology.
